A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
-
Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada))
;
Delord, Jean-Pierre (Institut Claudius Regaud (France)) ;
Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ;
Berge, Y. (Institut Claudius Regaud (France)) ;
Pérez-Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Cottura, E. (Institut Claudius Regaud (France)) ;
Bedard, Philippe L (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Akimov, Mikhail (Novartis Pharma AG (Switzerland)) ;
Lu, H. (Novartis Pharmaceuticals Corp (USA)) ;
Pain, S. (Novartis Pharmaceuticals Corp (USA)) ;
Kaag, A. (Novartis Pharma AG (Switzerland)) ;
Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Cortés, Javier (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona